News Releases
This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
02 03 2022 - Full year revenues of $10.79 billion, up 14.3% from 2020Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December...
-
02 02 2022 Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been selected as one of FORTUNE's World's Most Admired Companies in 2022...
-
01 31 2022 Convenient, physician-guided medical insights help people manage health without a trip to the doctor's officeQuest Diagnostics (NYSE: DGX) announced that they will now offer consumer-initiated laboratory testing powered by QuestDirect™ in collaboration with Walmart. The new solution allows people to...
-
01 28 2022 Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has received a score of 100% on the Human Rights Campaign Foundation's 2022...
-
01 26 2022 The ELF™ Test is the first and only prognostic blood test granted De Novo marketing authorization to assess disease progression in NASH patients. The ELF Test is now available nationwide through collaborations with Labcorp and Quest Diagnostics.TARRYTOWN, N.Y.--(BUSINESS WIRE)--The Enhanced Liver Fibrosis (ELF) Test from Siemens Healthineers is now available in the United States, providing broad clinical access to the minimally invasive...